Information Provided By:
Fly News Breaks for September 13, 2019
Sep 13, 2019 | 04:59 EDT
BofA/Merrill analyst Sachin Jain upgraded Genmab to Buy from Neutral with an increased price target of DKK1700. Multiple pipeline updates over the next 12 months should allow the investment thesis to begin to move beyond Darzalex and be a catalyst for the shares, Jain tells investors in a research note.
News For GMAB From the Last 2 Days
There are no results for your query GMAB